Sentence: Ferumoxytol magnetic resonance imaging for non-invasive pregnancy 6 monitoring of the rhesus macaque does not impact histopathology or iron content of the 7 maternal-fetal interface.
negative impact from ferumoxytol injection on the histopathology at the MFI, or evidence of 1 1 5 ferumoxytol transfer to the fetus, as assessed by iron content in MFI and fetal tissues These pregnancy well-being. activating agents (50 ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma-Aldrich, St. Louis 1 3 5 MO)) for all cell types, 750 ng/ml ionomycin (Sigma-Aldrich, St. Louis MO) for monocytes 1 3 6 only). Following incubation, cells were washed and fixed with 2% paraformaldehyde (PFA) for 1 3 7 visualization of iron content by Prussian Blue staining [25] [26] [27] . Cells were imaged using a Nikon 1 3 8
Eclipse TE300 microscope with NIS-Elements image capture. were imaged using a Nikon Eclipse TE300 microscope with NIS-Elements image capture. To visualize cellular iron content, isolated, fixed immune cells grown on coverslips or 1 5 0 deparaffinized rehydrated tissue sections were incubated in Prussian blue solution [25] [26] [27] for 20 1 5 1 minutes, washed with deionized water, and mounted with Aquapolymount (Polysciences, 1 5 2 Warrington PA). Female rhesus macaques in the Wisconsin National Primate Center (WNPRC) breeding 1 5 6 colony were housed with compatible males and monitored for breeding and menses. Pregnancies were confirmed and dated (+/-2 days) based on menstrual cycle, observation of copulation, and 1 5 8 9 There were two imaging phases in this study. In the first phase (Supplemental Fig. 1 A) , 1 6 7 seven pregnant macaques were imaged, three with ferumoxytol and four without, to establish 1 6 8 standard methods for anesthesia, imaging, and pilot scan settings with pregnancies proceeding to 1 6 9 term. Infants joined the WNPRC colony and body weights during the first year of life were 1 7 0 compared to 116 untreated macaque infants born at the WNPRC in 2016 to determine if MRI 1 7 1 during pregnancy impacted postnatal growth. Mean and standard deviation for these colony 1 7 2 infants were calculated at different ages, similar to the approach previously published [28]. Weights of infants exposed to MRI with or without ferumoxytol in-utero that were then born into 1 7 4 the colony were compared to this WNPRC 2016 colony growth chart through their first year of 1 7 5 life. In the second phase (Supplemental Fig. 1 B) , we used a paradigm of ferumoxytol MRI 1 7 9
following intra-amniotic injection of 10mg IL-1β (has been reported previously to increase inflammation [14, [18] [19] [20] [21] [22] at the MFI. Untreated controls (n=4) did not receive intra-amniotic 1 8 3 injections, ferumoxytol, or MRI. While the resulting R2* maps from IL-1β-exposed animals did ferumoxytol MRI at the MFI or on the fetus. aspect of the abdomen. A syringe filled with sterile saline was attached to a biopsy needle and 1 9 1 inserted through an aseptically prepared site of the abdominal wall until the tip reached the wall 1 9 2 of the uterus, avoiding the bowel and bladder (n=4, Supplemental Fig. 1 B) . The needle was 1 9 3 advanced into the amniotic cavity and a small amount of amniotic fluid was drawn to confirm 1 9 4 needle placement. The contents of the syringe were then slowly injected into the amniotic cavity, 1 9 5 and the needle was withdrawn. Following withdrawal of the needle, the insertion site in the 1 9 6 uterus was observed by ultrasound to confirm lack of bleeding. All animals that underwent an MRI exam, regardless of whether they also received 2 0 0 ferumoxytol, were sedated by injection of up to 10 mg/kg ketamine, intubated, and anesthesia 2 0 1 was maintained by inhalation of oxygen and 1.5% isoflurane. A pulse oximeter probe was placed 2 0 2 and vital signs were monitored every 15 minutes. Animals were imaged in the right-lateral 2 0 3 position and a respiratory bellow was placed around the animal's belly during imaging to enable 2 0 4 respiratory-compensated imaging that minimizes motion-related artifacts. Animals that received 2 0 5 ferumoxytol had an intravenous catheter placed for injection during imaging. weighted DCE images with 5 second temporal resolution were obtained throughout the 2 1 0 ferumoxytol administration [17] . Ferumoxytol diluted 5:1 with normal saline was administered at 2 1 1 4 mg/kg body weight over a 20 second interval using a power injector, followed by a 20 ml 2 1 2 saline flush at the same rate. A baseline R2* MRI scan (an MRI relaxation parameter highly 2 1 3 correlated and sensitive to detect iron concentration) was performed before ferumoxytol 2 1 4 administration. R2* measurements were estimated in the maternal, MFI, and fetal tissues by Fetal and MFI tissues were dissected for histology, iron content mass spectrometry, and protein 2 2 5 assay. homogenized in a Bullet Blender (Next Advance, Troy NY) at full power for 10 minutes with 2 3 0 non-metal blending beads and 500 µL PBS. Tissue homogenate was stored at -80°C until use. A 2 3 1 96-well format micro BCA protein assay (Thermo Scientific, 23235) was used to determine 2 3 2 protein concentrations in homogenates assayed for iron content according to the manufacturer's previously reported [35, 36] .The limit of detection is 30pg/ml for progesterone; 6pg/ml for 2 4 5 estrone and estradiol. and routinely processed and embedded in paraffin. 5µm sections were stained with H&E and 2 5 0 assessed by veterinary pathologists blinded to treatment groups. Tissues were evaluated for the remodelling and/or the lack thereof), and non-vascular necrosis across the tissue section or organ To determine whether rhesus macaque cells take up ferumoxytol as reported with human 2 7 0 cells [14, [18] [19] [20] [21] [22] , prior to initiating the imaging phases of this study, rhesus monocytes, 2 7 1 macrophages, and neutrophils were incubated in 100 µg/ml ferumoxytol (Fig. 1) , the 2 7 2 approximate concentration of ferumoxytol in the blood with administration for MRI, and iron not monocytes or neutrophils. Activation with PMA and ionomycin did not affect iron staining. No staining was seen without ferumoxytol incubation. To determine whether placental ferumoxytol uptake by placental tissue may confound 2 7 9
use for inflammation mapping in vivo, prior to initiating the imaging phases of this study, rhesus iron staining was observed after 2 hours of ferumoxytol-incubation. An increase in iron staining 2 8 4 appeared after 24 hours incubation, specifically in the villous endothelium of the placental tissue. Not substantial staining of the syncytiotrophoblasts was observed, the primary interface exposed 2 8 6
to ferumoxytol in maternal blood in vivo. Low levels of endogenous iron and modest increases in In addition to the 7 animals in this study that received ferumoxytol for MRI 2 9 3 (Supplemental Fig. 1 administration of ferumoxytol that was treated with 10 mg diphenhydramine hydrochloride. One 2 9 8
animal had a short period of increased heart rate and SPO2 levels. This animal had previous 2 9 9
ocular swelling not associated with ferumoxytol, so it is unclear whether this event was due to 3 0 0 ferumoxytol or other drugs used to anesthetize the animal. These mild allergic reactions 3 0 1 responded to diphenhydramine and the animals recovered without further medical intervention. imaging studies are described in separate reports [17, 38] . Pregnancy outcomes were generally 3 0 7 unremarkable, with one retained placenta (which occurs in ~2.6% of WNPRC pregnancies).
3 0 8
None of the seven dams had immediate or long-term reactions to the ferumoxytol treatment. Infant growth data from these pregnancies are plotted along with their birth year cohort 3 1 0 weights (Fig. 2) animals, an increase in R2* values in both the primary and secondary placental disks is seen 3 2 2
immediately following ferumoxytol injection (Fig. 3) . he R2* values in fetal lung remained close animals. This may reflect an increase in physiological iron transport to the fetus over time in within one day post-ferumoxytol, supporting a rapid clearance of ferumoxytol from the blood. Ferumoxytol accumulation in the placenta or transfer to the fetus was not detectable by R2* (Zhu Maternal, MFI, and fetal tissues from 8 pregnancies (Supplemental Fig. 1 B) were surgically collected at ~gd100 following MRI and iron concentrations were determined in these 3 3 4 tissues (Fig. 4) . When ferumoxytol-exposed and untreated control groups were compared, only 3 3 5 maternal liver showed a significant increase in iron concentration with maternal ferumoxytol 3 3 6 administration over control (p<0.0001). There are no significant differences in iron in fetal 3 3 7 tissues in ferumoxytol vs. non-ferumoxytol-exposed animals. For each imaging day in animals that underwent fetectomy (Supplemental Fig. 1 B) , estradiol levels [35, 36] to assess the impact of MRI imaging and ferumoxytol administration on 3 5 0 placental endocrine function. Non-imaged controls (Supplemental Fig. 1 B) received a one-time within the range of levels seen in non-imaged controls (Fig. 5 ). Of 37 maternal and fetal tissues collected at fetectomy (Supplemental Data 1), the 3 5 7 placenta, decidua, amniotic membranes, placental bed, maternal spleen, and maternal liver had 3 5 8 notable histopathology. Animals that did and did not receive ferumoxytol MRI had no 3 5 9 statistically significant differences in individual tissue histopathology scores (Fig. 6 ). MRI with ferumoxytol. It should be noted that ferumoxytol was injected as a diluted bolus in this 3 7 0 study, while it is administered as a slow infusion in humans to reduce the risk of anaphylactic reactions. The lack of significant adverse outcomes in the rhesus subjects also suggests the utility 3 7 2 of ferumoxytol as a non-gadolinium contrast agent for MRI in pregnancy studies. The use of ferumoxytol in MRI of pregnancy has the potential to yield important rates of blood into the individual cotyledons can be determined, which may be related to the to detect the accumulation of phagocytic macrophages at sites of inflammation. Tissue 3 9 0 macrophages take up ferumoxytol and clear these iron nanoparticles more slowly than those in 3 9 1 the blood, therefore, sites of inflammation can be located by performing delayed imaging 3 9 2
following ferumoxytol administration. This paradigm may help identify inflammation at the 3 9 3 MFI, which could predict an insult to the pregnancy. Concerns about ferumoxytol uptake by the placenta and the potential for transport of were focally distributed areas of iron detected by Prussian Blue staining, however interestingly, 4 1 7
the tissues with the clearest demonstration of iron content were the decidua and fetal membranes 4 1 8 rather than the placental villi. It is important to note that the animal in which iron was most 4 1 9
readily demonstrated in these tissues did not receive ferumoxytol and thus SPION-delivered iron 4 2 0
was not the source of Prussian Blue staining. These data suggest that although the placenta mediated endocytosis [43] [44] [45] . We hypothesize that cellular iron sequestration, as indicated by 4 2 6
22
Consistent with a lack of increase in iron content of MFI tissues by histochemical 4 2 9
methods, there was no significant increase in iron concentration in MFI tissues by mass 4 3 0 spectrometry. Likewise, fetal tissues that would be anticipated to accumulate iron, did not show a 4 3 1 statistically significant increase. While there does appear to be a trend for slightly higher, though 4 3 2 not statistically significant, iron content in fetal tissues, further studies will be needed to 4 3 3 determine if this is a consistent result. There was a statistically significant increase in maternal 4 3 4 liver iron content, which was expected since the liver is a main clearance organ for ferumoxytol, Histopathology was evaluated in selected maternal tissues, the MFI, and in fetal tissues.
3 8
There was no detectable histopathology in any fetal tissues. While histopathology was noted in 4 3 9
tissues at the MFI, there were not significant differences between ferumoxytol-receiving and The data presented in this report were part of a larger study in which some fetuses The use of an animal model to evaluate MRI methodologies has significant advantages.
6 3
The pregnant dam is anesthetized for the imaging procedure in the nonhuman primate model, body imaging applications (i.e. cardiac, lung, abdominal) where motion is of substantial concern 4 7 7
for producing diagnostic quality MR images..
7 8
In summary, we conclude that ferumoxytol administration for imaging in this rhesus 4 7 9
pregnancy model is feasible. Future studies will explore the use of ferumoxytol to detect Macaque. J Magn Reson Imaging 2018. from dams and fetuses at fetectomy after ferumoxytol MRI, or from untreated pregnancies. 
